Editas Medicine, Inc.
EDIT
Price:
$2.44
Market Cap:
$201.42M
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In additio...[Read more]
Industry
Biotechnology
IPO Date
2016-02-03
Stock Exchange
NASDAQ
Ticker
EDIT
PE Ratio
[-0.96]
ROE
[-80.13%]
Current Ratio
[3.75]
Dividend Yield
[0%]
Enterprise Value
[144.07M]
Dividend History
The ROE as of November 2024 (TTM) for Editas Medicine, Inc. (EDIT) is -80.13%
According to Editas Medicine, Inc.’s latest financial reports and current stock price. The company's current ROE is -80.13%. This represents a change of 252.34% compared to the average of -22.74% of the last 4 quarters.
Editas Medicine, Inc. (EDIT) Historical ROE (quarterly & annually)
How has EDIT ROE performed in the past?
The mean historical ROE of Editas Medicine, Inc. over the last ten years is -20.82%. The current -80.13% ROE has changed 284.86% with respect to the historical average. Over the past ten years (40 quarters), EDIT's ROE was at its highest in in the December 2014 quarter at 35.38%. The ROE was at its lowest in in the June 2015 quarter at -337.45%.
Average
-20.82%
Median
-45.22%
Minimum
-72.20%
Maximum
89.49%
Editas Medicine, Inc. (EDIT) ROE by Quarter and Year
Discovering the peaks and valleys of Editas Medicine, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 69.46%
Maximum Annual ROE = 89.49%
Minimum Annual Increase = -182.31%
Minimum Annual ROE = -72.20%
| Year | ROE | Change |
|---|---|---|
| 2023 | -43.89% | -22.53% |
| 2022 | -56.66% | 69.46% |
| 2021 | -33.43% | 20.27% |
| 2020 | -27.80% | -40.91% |
| 2019 | -47.05% | 1.05% |
| 2018 | -46.56% | -19.48% |
| 2017 | -57.83% | -19.91% |
| 2016 | -72.20% | -182.31% |
| 2015 | 87.71% | -1.99% |
| 2014 | 89.49% | -70.50% |
Editas Medicine, Inc. (EDIT) Average ROE
How has EDIT ROE performed in the past?
The current ROE of Editas Medicine, Inc. (EDIT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-44.66%
5-year avg
-41.77%
10-year avg
-20.82%
Editas Medicine, Inc. (EDIT) ROE vs. Peers
How is EDIT’s ROE compared to its peers?
Editas Medicine, Inc.’s ROE is greater than Beam Therapeutics Inc. (-16.22%), greater than CRISPR Therapeutics AG (-12.15%), greater than Caribou Biosciences, Inc. (-45.46%), greater than Verve Therapeutics, Inc. (-35.23%), greater than Intellia Therapeutics, Inc. (-51.97%), greater than Prime Medicine, Inc. (-114.95%), greater than Vertex Pharmaceuticals Incorporated (-2.88%), greater than Ginkgo Bioworks Holdings, Inc. (-70.11%), greater than Allogene Therapeutics, Inc. (-58.07%), greater than Sana Biotechnology, Inc. (-94.47%),
| Company | ROE | Market cap |
|---|---|---|
| -16.22% | $2.07B | |
| -12.15% | $4.09B | |
| -45.46% | $182.92M | |
| -35.23% | $410.62M | |
| -51.97% | $1.46B | |
| -114.95% | $419.71M | |
| -2.88% | $116.14B | |
| -70.11% | $412.70M | |
| -58.07% | $463.38M | |
| -94.47% | $582.73M |
Build a custom stock screener for Editas Medicine, Inc. (EDIT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Editas Medicine, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Editas Medicine, Inc. (EDIT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Editas Medicine, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Editas Medicine, Inc.'s ROE?
How is the ROE calculated for Editas Medicine, Inc. (EDIT)?
What is the highest ROE for Editas Medicine, Inc. (EDIT)?
What is the 3-year average ROE for Editas Medicine, Inc. (EDIT)?
What is the 5-year average ROE for Editas Medicine, Inc. (EDIT)?
How does the current ROE for Editas Medicine, Inc. (EDIT) compare to its historical average?